273 related articles for article (PubMed ID: 17372640)
1. Ruthenium complexes can target determinants of tumour malignancy.
Bergamo A; Sava G
Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.
Sava G; Gagliardi R; Bergamo A; Alessio E; Mestroni G
Anticancer Res; 1999; 19(2A):969-72. PubMed ID: 10368640
[TBL] [Abstract][Full Text] [Related]
3. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
Bicek A; Turel I; Kanduser M; Miklavcic D
Bioelectrochemistry; 2007 Nov; 71(2):113-7. PubMed ID: 17602896
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
Bergamo A; Sava G
Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
7. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
8. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
Magnarin M; Bergamo A; Carotenuto ME; Zorzet S; Sava G
Anticancer Res; 2000; 20(5A):2939-44. PubMed ID: 11062704
[TBL] [Abstract][Full Text] [Related]
9. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
10. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
11. Drug control of solid tumour metastases: a critical view.
Sava G; Bergamo A
Anticancer Res; 1999; 19(2A):1117-24. PubMed ID: 10368662
[TBL] [Abstract][Full Text] [Related]
12. TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours.
Casarsa C; Mischis MT; Sava G
J Inorg Biochem; 2004 Oct; 98(10):1648-54. PubMed ID: 15458828
[TBL] [Abstract][Full Text] [Related]
13. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
Khalaila I; Bergamo A; Bussy F; Sava G; Dyson PJ
Int J Oncol; 2006 Jul; 29(1):261-8. PubMed ID: 16773208
[TBL] [Abstract][Full Text] [Related]
14. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Ravera M; Baracco S; Cassino C; Zanello P; Osella D
Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
[TBL] [Abstract][Full Text] [Related]
15. Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis ES; Emadi A
Cancer Chemother Pharmacol; 2010 May; 66(1):1-9. PubMed ID: 20213076
[TBL] [Abstract][Full Text] [Related]
16. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
[No Abstract] [Full Text] [Related]
19. Ruthenium anticancer drugs.
Alessio E; Mestroni G; Bergamo A; Sava G
Met Ions Biol Syst; 2004; 42():323-51. PubMed ID: 15206107
[No Abstract] [Full Text] [Related]
20. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
Bergamo A; Gaiddon C; Schellens JH; Beijnen JH; Sava G
J Inorg Biochem; 2012 Jan; 106(1):90-9. PubMed ID: 22112845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
